187 related articles for article (PubMed ID: 33428749)
1. PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma.
Benitez JA; Finlay D; Castanza A; Parisian AD; Ma J; Longobardi C; Campos A; Vadla R; Izurieta A; Scerra G; Koga T; Long T; Chavez L; Mesirov JP; Vuori K; Furnari F
Neuro Oncol; 2021 Jul; 23(7):1072-1086. PubMed ID: 33428749
[TBL] [Abstract][Full Text] [Related]
2. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
4. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
5. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
7. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
[TBL] [Abstract][Full Text] [Related]
8. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
Muh CR; Joshi S; Singh AR; Kesari S; Durden DL; Makale MT
J Neurooncol; 2014 Jan; 116(1):89-97. PubMed ID: 24162827
[TBL] [Abstract][Full Text] [Related]
9. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
10. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway.
Wang J; Ren D; Sun Y; Xu C; Wang C; Cheng R; Wang L; Jia G; Ren J; Ma J; Tu Y; Ji H
J Cell Mol Med; 2020 Apr; 24(7):3931-3947. PubMed ID: 32126150
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Synthetic Vulnerability of
Chen C; Zhu S; Zhang X; Zhou T; Gu J; Xu Y; Wan Q; Qi X; Chai Y; Liu X; Chen L; Yan J; Hua Y; Lin F
Mol Cancer Ther; 2020 Oct; 19(10):2001-2011. PubMed ID: 32737157
[No Abstract] [Full Text] [Related]
13. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
[TBL] [Abstract][Full Text] [Related]
14. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
15. EGFR signaling is differentially activated in patient-derived glioblastoma stem cells.
Howard BM; Gursel DB; Bleau AM; Beyene RT; Holland EC; Boockvar JA
J Exp Ther Oncol; 2010; 8(3):247-60. PubMed ID: 20734923
[TBL] [Abstract][Full Text] [Related]
16. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.
Zhu Y; Shah K
Cancer Biol Ther; 2014 Jun; 15(6):815-22. PubMed ID: 24658109
[TBL] [Abstract][Full Text] [Related]
17. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
Pitter KL; Galbán CJ; Galbán S; Tehrani OS; Li F; Charles N; Bradbury MS; Becher OJ; Chenevert TL; Rehemtulla A; Ross BD; Holland EC; Hambardzumyan D
PLoS One; 2011 Jan; 6(1):e14545. PubMed ID: 21267448
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.
Kaluzova M; Bouras A; Machaidze R; Hadjipanayis CG
Oncotarget; 2015 Apr; 6(11):8788-806. PubMed ID: 25871395
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic Smurf1 promotes PTEN wild-type glioblastoma growth by mediating PTEN ubiquitylation.
Xia Q; Zhang H; Zhang P; Li Y; Xu M; Li X; Li X; Dong L
Oncogene; 2020 Sep; 39(36):5902-5915. PubMed ID: 32737433
[TBL] [Abstract][Full Text] [Related]
20. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH
J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
